☆ 4.7 Letter

Anaphylaxis associated with omalizumab administration: Risk factors and patient characteristics

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)

Get Full Text
Add to Collection

Journal

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 140, Issue 6, Pages 1734-+

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2017.07.013

Keywords

-

Categories

Allergy Immunology

Funding

  1. Genentech, Inc, South San Francisco, Calif
  2. Novartis Pharma AG, Basel, Switzerland
  3. Genentech, Inc
  4. Novartis Pharmaceuticals Corporation

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.